The JAG1 knockout NCI-H1299 polyclonal cells constitute a population of the human non-small cell lung carcinoma cell line NCI-H1299 that has been genetically engineered through CRISPR/Cas9-mediated disruption of the JAG1 locus. This product delivers a polyclonal knockout model with heterogeneous editing events across the cell pool, resulting in abrogation of Jagged1 protein expression without the isolation of single-cell clones. It serves as a versatile loss-of-function system for dissecting Notch signaling pathway dynamics in a lung adenocarcinoma background, providing a physiologically relevant platform for functional genomics and pharmacological studies.
The parental NCI-H1299 cell line was derived from a metastatic lymph node of a 43-year-old Caucasian male diagnosed with lung adenocarcinoma and is widely recognized as a model for non-small cell lung carcinoma metastasis and epithelial-mesenchymal transition (EMT). These cells retain key characteristics of advanced lung cancer, including robust migratory and invasive capacity, and are routinely employed to investigate molecular mechanisms of tumor dissemination and stromal communication. The genetic context of NCI-H1299 offers a clinically pertinent framework for examining Jagged1-dependent Notch signaling contributions to metastatic progression.
JAG1 encodes Jagged1, a single-pass transmembrane ligand for Notch receptors. Binding of Jagged1 to NOTCH1, NOTCH2, or NOTCH3 on neighboring cells, facilitated by MIB1-mediated ubiquitination, triggers sequential proteolytic cleavage by ADAM17 and the gamma-secretase complex. This releases the Notch intracellular domain (NICD), which translocates to the nucleus and assembles a transcriptional activation complex with RBPJ and Mastermind-like co-activators (MAML). The complex directly induces expression of canonical targets such as HES1, HEY1, MYC, CCND1, and SNAI1, thereby controlling cell fate, proliferation, and differentiation. Upstream regulators including NFKB1, TGFB1, HIF1A, and the MAPK/ERK cascade converge on JAG1 transcription, integrating multiple extracellular signals to modulate Notch pathway activity.
In the NCI-H1299 metastatic lung adenocarcinoma context, Jagged1-driven Notch signaling has been implicated in promoting EMT, enhancing cellular motility and invasiveness, and mediating paracrine crosstalk with tumor stromal components. Knockout of JAG1 in these polyclonal cells enables precise interrogation of Notch-dependent processes governing metastatic behavior, including the regulation of SNAI1 and other EMT transcription factors downstream of NICD. This model provides a system to evaluate the contribution of Jagged1 to anchorage-independent growth, chemoresistance, and angiogenic signaling, all critical to the aggressive phenotype of non-small cell lung carcinoma.
Typical applications encompass quantitative measurement of Notch transcriptional output using HES1/HEY1 luciferase reporters, co-culture signaling assays to assess Jagged1-Notch communication between knockout cells and stromal partners, and migration/invasion assays to evaluate EMT-driven motility. The polyclonal knockout architecture reduces clonal bias and permits robust detection of pathway-level alterations via bulk RNA-seq, western blotting for NOTCH1 cleavage products, and immunofluorescence analysis of NICD nuclear translocation. For further technical information, please contact Ascent Research.
